Advertisement

Employment/Membership › Details
Univ Oxford–Roxborough H: management, 202203– Partner Health Tech at Oxford Science Enterprises before Optum Ventures + JnJ Innovations + Tate+Lyle VC
![]() |
Period | 2022-03-31 |
![]() |
Organisation | Oxford Science Enterprises plc |
Group | University of Oxford | |
Organisation 2 | Optum Ventures (OV), London | |
![]() |
Product | venture capital |
Product 2 | HEALTH (HUMAN) | |
Oxford Science Enterprises. (3/31/22). "Press Release: Oxford Science Enterprises Strengthens Investment Teams with Two New Appointments".
> Heather Roxborough PhD, former Partner at Optum Ventures, joins as Partner, Health Tech
> Wallace Wallace MPhil, former Associate at M-Ventures, joins as Associate, Life Sciences
Oxford Science Enterprises, the Science Business Builder and preferred investment partner of the University of Oxford, today announces further strengthening of its investment teams with the appointments of Heather Roxborough PhD as Partner, Health Tech and Wallace Wallace MPhil as Associate, Life Sciences.
As Partner, Heather will lead the Health Tech investment team to identify cutting-edge science and technology from the University’s world leading academics, drive investments into new spinouts and support the scale up of existing enterprises. Wallace joins the growing Life Sciences team to support the creation of new businesses and ongoing work across the current portfolio.
Alexis Dormandy, CEO Oxford Science Enterprises, said: “I am thrilled to welcome Heather and Wallace. Heather brings over 15 years of investment and leadership experience, with a strong track record of deal-making and company building to lead the Health Tech team. While Wallace’s experience in scientific due diligence and early-stage investing strengthens the Life Sciences team. These appointments continue to demonstrate our commitment and enhanced ability to identify, support and commercialise the University of Oxford’s cutting-edge science in order to build world-leading businesses.”
Heather Roxborough PhD, Partner, Health Tech
Heather is a highly experienced venture capitalist, with over 15 years of investment and company building experience from across a range of sectors, including health tech, consumer healthcare, pharmaceuticals, medical devices and food technology.
Heather joins Oxford Science Enterprises from Optum Ventures where she was a Partner, responsible for establishing and leading the global health tech investment fund on behalf of Optum, a leading technology-enabled US health services business, part of UnitedHealth Group.
Heather has also held investment roles at J&J Innovations as Senior Director and Tate and Lyle Ventures as Principal. She holds a PhD in Clinical Biochemistry from Queen’s University of Belfast.
Wallace Wallace MPhil, Associate, Life Sciences
Wallace joins Oxford Science Enterprises from M-Ventures, the corporate venture capital arm of Merck KGaA, where she supported the life sciences investment team across scientific due diligence and portfolio management.
Prior to this, Wallace worked at Accenture as a consultant, assisting the Business Strategy and Operation Strategy units, advising financial services clients.
She holds a BSc in Genetics from the University of York and an MPhil in Bioscience Enterprise from the University of Cambridge.
ENDS
About Oxford Science Enterprises
We are Oxford Science Enterprises, the Science Business Builder. We want to help solve the world’s toughest problems for more people, in more places, faster. We do this by transforming world-leading science into world-changing businesses, partnering the best scientists from the world’s best university with the best business brains. We grow our companies with care and expertise; in a way that is systematic and scalable. We invest for real-world impact, not only financial returns. And we re-invest proceeds back into the next generation of original research and world-changing businesses.
Our enterprises address problems that affect people in life-changing ways: their health, the availability of food, the survival of the planet. Since 2015, we have received an automatic stake in all Oxford University science spinouts – more than 100 businesses founded by over 200 of Oxford’s leading academics. We have taken a leading role in creating and building over 70 of these, adding +55,000 sq ft of lab & start-up space to support them. Today our businesses are worth over £2bn and have created +2,000 jobs.
Follow us: oxfordscienceenterprises.com | Twitter | LinkedIn | Quarterly News
Contacts:
Oxford Science Enterprises
Lisa Bedwell – lbedwell@oxfordsciences.com
For media enquiries:
Mark Swallow, Sandi Greenwood, Eleanor Perkin – MEDiSTRAVA Consulting
oxfordsciences@medistrava.com
Record changed: 2022-05-23 |
Advertisement
![Picture [iito] Männer Ballett 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-maenner-ballett.jpg)
More documents for University of Oxford
- [1] Oxford Science Enterprises. (3/31/22). "Press Release: Oxford Science Enterprises Strengthens Investment Teams with Two New Appointments"....
- [2] Exscientia Ltd.. (8/4/21). "Press Release: Exscientia Builds Automated Laboratories in Oxford to Expand Pipeline"....
- [3] AstraZeneca plc. (12/30/20). "Press Release: AstraZeneca’s COVID-19 Vaccine Authorised for Emergency Supply in the UK"....
- [4] Enara Bio Ltd.. (12/9/20). "Press Release: Enara Bio Relocates to The Oxford Science Park’s Newest Facility to Expand R&D Capabilities in the Search for Novel Vancer Immunotherapies". Oxford & London....
- [5] Evotec SE. (9/2/20). "Press Release: Evotec Expands Its Proprietary Patient Database into Liver Disease with Unique Access to QUOD Biobank". Hamburg....
- [6] Base Genomics Ltd.. (6/3/20). "Press Release: Base Genomics Announces Company Launch and Raises $11 Million USD to Commercialize Epigenetic Technology for Early and Sensitive Detection of Cancer from Liquid Biopsy". Oxford....
- [7] Halix B.V.. (4/15/20). "Press Release: Halix Enters Collaboration with the University of Oxford for GMP Manufacturing of a COVID-19 Vaccine". Leiden....
- [8] Oxford University Innovation. (1/23/20). "Press Release: Oxford Investment Opportunity Network and Oxford Angel Network Join Forces"....
- [9] Bicycle Therapeutics plc. (10/22/19). "Press Release: Bicycle Therapeutics Expands Neuroscience Collaborations to include Oxford University’s Oxford Drug Discovery Institute". Cambridge & Boston, MA....
- [10] MiroBio Ltd.. (10/7/19). "Press Release: MiroBio Launches with £27m ($34m) Series A from Leading Life Sciences Investors". Oxford....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top